Next Article in Journal
Effects of H2S Loading Rate on the Performance of Reactive Absorption with Electrochemical Oxidation
Previous Article in Journal
A Two-Stage Hybrid Metaheuristic for a Low-Carbon Vehicle Routing Problem in Hazardous Chemicals Road Transportation

Management of Patients under Treatment with Monoclonal Antibodies and New Biological Therapies

Department of Medicine and Orofacial Surgery, Faculty of Dentistry, Complutense University of Madrid, 28040 Madrid, Spain
Author to whom correspondence should be addressed.
Academic Editor: Francesco Cappello
Appl. Sci. 2021, 11(11), 4865;
Received: 28 April 2021 / Revised: 21 May 2021 / Accepted: 22 May 2021 / Published: 25 May 2021
(This article belongs to the Topic Human Anatomy and Pathophysiology)


Objective: The aim of this study is to know the biological therapy drugs that are related to adverse events, what dental treatments are associated with the appearance of these events, their severity, and how they are resolved. Study design: Analysis of cases described in the literature on patients undergoing treatment with biological therapies who have developed adverse effects associated with these drugs. Results: Of the 62 articles reviewed, 49 describe 68 cases of MRONJ, most of which appeared in the jaw and received surgical and/or conservative treatment. Conclusions: Biological therapies can potentially develop adverse effects in the oral cavity, so strict monitoring by the dentist is necessary.
Keywords: target therapy; antiangiogenic agent; denosumab; osteonecrosis of the jaw; monoclonal antibody; stomatitis; dental infection; MRONJ target therapy; antiangiogenic agent; denosumab; osteonecrosis of the jaw; monoclonal antibody; stomatitis; dental infection; MRONJ

1. Introduction

Biological therapies are a new method of treating some autoimmune diseases and cancer. They were defined by the FDA (Food and Drugs Administration) as any virus, therapeutic serum, toxin, antitoxin, or similar product applicable to the prevention and treatment of human diseases. These biologics include vaccines, blood and blood-derived preparations, antitoxins, growth hormones, human insulin, gene therapies, recombinant therapies, proteins, and allergens, along with the newer biologics: cytokines, monoclonal antibodies, and fusion proteins [1,2].
Cytokines are immunomodulators that regulate the host’s response to inflammation and infections. In this way they work by signaling molecules that will bind to protein receptors on cells, generating a physiological change in them.
Monoclonal antibodies are synthetic molecules that activate against certain antigens to improve immune recognition. They are divided into four subgroups: murine, chimeric, humanized, and human.
Fusion proteins are composed of transmembrane proteins connected to another molecule through the Fc portion of human immunoglobulin.
The mechanisms of action of biological therapies involve a series of physiological changes that can trigger side effects in the patient. One of these mechanisms is the inhibition of molecules such as TNFα, which are essential in the inflammatory response. This produces a change in the immune system that can lead to these patients having a greater predisposition to infections [1].
Other mechanisms of action to take into account, due to their physiological repercussions, are antiresorptive and antiangiogenic, influencing osteoclasts and vascular endothelial growth factor (VEGF), respectively [2,3].
Despite the efficacy and safety of these drugs in the vast majority of patients, there is a significant risk of producing adverse effects such as mucositis, hyperkeratotic lesions, mucosal dyschromia, geographic tongue, dysgeusia, lichenoid lesions, telangiectasias, xerostomia, dysesthesia, and, the most prominent, osteonecrosis of the jaw, due to its antiangiogenic and/or antiresorptive power [4]. This osteonecrosis will be considered related to these medications when the following characteristics described by the AAOMS (American Association of Oral and Maxillofacial Surgeons) are present in a patient:
Previous or current treatment with antiresorptive or antiangiogenic agents.
Exposed bone or bone that can be probed through an intra- or extra-oral fistula in the maxillofacial region, which has persisted for more than 8 weeks.
Absence of radiotherapy or previous metastasis in the jaw [2].
In 2014, the AAOMS changed the term “Bisphosphonate-Related Osteonecrosis of the Jaws” (BRONJ) to “Medication-related Osteonecrosis of the Jaws” (MRONJ) to include all other drugs related to osteonecrosis. However, since 2017 there are only three monoclonal antibodies officially recognized by the FDA as causing MRONJ: denosumab, bevacizumab, and sunitinib. The rest of the reported drugs have not yet been recognized as such due to the lack of scientific evidence [5].
The objective of this study is to know the drugs related to adverse events in oral surgery, what effects they produce, and to record how they have been resolved according to the available literature.

2. Material and Methods

An electronic search was carried out in the National Library of American Medicine (MEDLINE) through Pubmed, with the combination of the following terms: “MRONJ”; “Adverse effect” AND “dental disease” AND “targeted therapy”, applying the results filters by year between 2005 and 2020, in humans, and with the full text available.
The following inclusion criteria were established: articles published since 2005, but due to the lack of described literature on the subject, the search was extended to those published since 2005; in English or Spanish; performed in humans; patients being treated with biological therapies; and in relation to the objective of this review. Following the exclusion criteria, those articles published prior to 2005 were eliminated from the search; in a language other than Spanish or English; performed on animals; those duplicates; and those that, after reading the abstract, were not related to the main objective of this review.

3. Results

A total of 374 articles were obtained, to which the criteria described above were applied, going to read full text 83 articles, and finally selecting a total of 54 for this review (Figure 1).
Within our selection, a total of 49 articles have been compiled in relation to osteonecrosis of the jaws [5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22], two articles in relation to lesions in the oral mucosa [4,23], two with oral infections [24,25], and, finally, one article reporting a case of exudative erythema multiforme [26] (EEM) associated with the use of biological therapies.
Of the total of 49 articles related to osteonecrosis of the jaws, 14 cases were collected that refer to bevacizumab [10,27,28,29,30,31,32,33,34,35,36,37,38,39], eight cases to sunitinib [17,18,19,20,21,22,29,39], six cases to denosumab [10,11,12,13,14] and everolimus [29,39,40,41,42,43], five cases to rituximab [5,11,12,13,14], four cases to temsirolimus [14,26,29,34], three cases referred to sorafenib [19,29,33] and aflibercept [44,45,46], two cases related to trastuzumab and pertuzumab [15,39], imatinib [39,47], and pazopanib [39,42]. Finally, only one article was found referring to tacrolimus [5], lenvatinib [16], erlotinib [33], ipilimumab [48], cabozantinib [49], afatinib [39], nilotinib [39], dasatinib [39], or tocilizumab [50].
Regarding the treatment carried out for osteonecrosis, in a total of 38 cases a surgical treatment was carried out, in 23 cases a conservative treatment was carried out, and in seven of them the treatment followed was not specified.
The surgical act is the triggering factor reported in most cases, with a total of 27; this is followed by a poor fit of the prostheses, mentioned in five cases; finally, in 31 the triggering factor for osteonecrosis is not described and in the remaining five cases a factor other than those previously mentioned is related.
Oral complications related to biological therapies have been found, such as lesions at the mucosal level as described in the reviews of the literature by Vigarios et al. [4] (2017) and Watter et al. [23] (2011). Cases of infections at the oral level have been reported in patients treated with adalimumab and infliximab, as described by Cillo et al. [24] (2019) and Filler et al. [25] (2005), as well as a case of exudative erythema multiforme (EEM) in a patient treated with infliximab as described by Edwards et al. [26] (2013). Within the literature, the complication of which more cases have been found is osteonecrosis of the jaws, in patients receiving one or more biological therapies (Figure 2).
Within our search, 49 articles containing a total of 68 cases establish a possible relationship of biological therapies with osteonecrosis of the jaws (Table 1). In 62.69% of the cases, osteonecrosis was related to denosumab (16.42%), an antiresorptive agent; bevacizumab (28.36%) or sunitib (17.91%), both antiangiogenic agents, coinciding with the three drugs described in 2014 by the AAOMS as producers of MRONJ.
Among them, it can be observed that there are more cases of osteonecrosis in the mandible (83.58%) than in the maxilla, as well as a higher frequency in men, with 53.73%. Regarding the treatment carried out for osteonecrosis, it can be observed that a surgical treatment was carried out in 55.22% of the cases, which consists in the majority of them in a mandibular sequestrectomy or resection. Conservative treatment consists mainly of antibiotic therapy, antimicrobial rinses, strict oral hygiene measures, as well as modifications in biological therapy.

4. Discussion

Although osteonecrosis is the most studied complication due to its severity, there are also references to other complications at the oral level. Although these complications do not involve such a high risk for the patient, they require treatment to control and improve their quality of life.
These drugs can be difficult to identify clinically by their brand names. A table (Table 2) is presented with the drugs and their most common commercial name to facilitate their identification for the professional, as well as a series of recommendations on the management of patients with biological therapy.

4.1. Management of Patients Undergoing Treatment with Biological Therapies

The management of patients undergoing treatment with these biological therapies requires monitoring and special measures by the dentist to avoid the adverse effects previously described.
Before starting therapy, it is essential to carry out a complete dental treatment. Dental treatment includes a comprehensive dental examination with orthopantomography and intraoral radiographs, extraction of teeth with impossible prognosis, conservative dental treatments and periodontal interventions, prosthesis adjustment, factor control risks such as tobacco and diabetes, as well as patient education on the importance of oral care.
Infection is one of the most important adverse effects, but not enough scientific evidence has been found to support the use of antibiotic prophylaxis in these patients when performing surgery. The considerations prior to a surgical treatment that we will have to take into account are [1]:
Complete blood count if the procedure involves bleeding.
Prothrombin time (PT) and INR, if the patient has liver damage. This is one of the possible adverse effects in long-term treatment with biological therapies [57].
Interruption of treatment with biological agents before the procedure. The so-called drug holiday is a subject of controversy between different authors. With bisphosphonates, drug holiday protocols exist before performing invasive surgical treatment, although continuing with the controversy, a recent study in Japan [58] suggests that the withdrawal of BPs would not reduce the risk of developing adverse effects after surgery such as osteonecrosis [59]. This may be due to the fact that BPs have a long-lasting skeletal retention, while biological drugs such as denosumab have a reversible effect. For this reason, the use of drug holiday in patients receiving denosumab could be endorsed. However, the temporary suspension of medications must be compatible with the underlying pathology and be authorized by the prescriber. To date, there is insufficient scientific evidence to confirm the effectiveness of the drug holiday [60,61].
Regarding the surgical technique used in this type of patients, it should be as atraumatic as possible and can be accompanied by the use of plasma rich in growth factors (PRGF) to promote bone and soft tissue regeneration after surgery, reducing thus the risk of infection, and the time of exposure of the wound to bacteria. After surgery, experts recommend the use of antimicrobial rinses and systemic antibiotics.

4.2. Management of Complications Associated with Biological Therapies

Oral toxicities are one of the adverse effects in treatment with biological therapies. The management of these oral toxicities consists of:
Mucositis, stomatitis, and aphthous lesions: Basic oral care, corticosteroids (topical, intralesional, or oral), morphine rinses, systemic analgesics, LLLT (Low Level Laser Therapy), and change in medication and interruption of previously agreed radiotherapy sessions with the oncologist.
Hyperkeratotic lesions and dyschromia of the mucosa: Monthly reviews and biopsy in case of suspicion.
Geographic tongue: Avoidance of irritants, rinsing with corticosteroids in painful lesions.
Dysgeusia: Nutritional recommendations such as abundant consumption of liquids and cold meals; Changes in the medication previously agreed with the dentist can be proposed.
Lichenoid lesions: Topical corticosteroids for painful lesions and periodic reviews, as well as change in medication.
Telangiectasias and mucosal bleeding: Basic oral care and change in medication.
Xerostomía: Basic oral care, hydration, use of sialogogues such as pilocarpine or artificial salivary substitutes (palliative).
Dysestesia: Basic oral care, avoidance of irritants and symptomatic treatment with analgesics. In case of neuropathy, use drugs such as clonazepam or gabapentin.
MRONJ: This complication is divided by the AAOMS into four grades with a specific treatment for each of them [2]. (Table 3)
It has been observed that the use of hyperbaric oxygen therapy as an adjunct to surgical and non-surgical treatment produces improvements in wound healing, pain, and quality of life. However, there are no statistically significant differences with respect to the control group [2,62].
Other studies mention the use of low-frequency lasers, parathyroid hormone and BMPs (Bone Morphogenetic Protein) as strategies in non-surgical treatment, but more studies are needed to verify their efficacy [2].

4.3. Study Limitations

The present study meets a series of limitations: There is a lack of scientific evidence about the possible adverse effects that these drugs may present at the oral level, in addition, it is difficult to relate them to a single drug in polymedicated patients. Likewise, in most cases, the adverse event is not easily related to dental treatment due to the time elapsed until it appears.
Despite this, this review presents all the oral adverse events reported to date in relation to these drugs.

5. Conclusions

The biological drugs that, according to the literature described, have the greatest relationship with adverse events in the dental field are bevacizumab, denosumab and sunitinib. The main adverse event is osteonecrosis of the jaws (MRONJ), resolved in most of the cases described with surgical treatment.
It is necessary to take into account the oral complications associated with these therapies and the importance of monitoring by the dentist from the beginning, in order to prevent or reduce the appearance of these.
Despite the reported cases, more studies are needed to describe in a more exhaustive way the appearance of complications that could be related to these treatments.

Author Contributions

Conceptualization, M.A.-B. and C.Á.-G.; methodology, C.C.-V; data selection, I.L.-B., L.M.S.-A. and C.M.-G.; data extraction, M.A.-B.; writing—original draft preparation, C.Á.-G.; writing—review and editing, C.C.-V.; visualization, C.M.-G.; supervision, L.M.S.-A.; submission, C.C.V. All authors have read and agreed to the published version of the manuscript.


This research received no external funding.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Conflicts of Interest

The authors declare no conflict of interest.


  1. Radfar, L.; Ahmadabadi, R.E.; Masood, F.; Scofield, R.H. Biological therapy and dentistry: A review paper. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 2015, 120, 594–601. [Google Scholar] [CrossRef] [PubMed]
  2. Ruggiero, S.L.; Dodson, T.B.; Fantasia, J.; Goodday, R.; Aghaloo, T.; Mehrotra, B.; O’Ryan, F. American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw—2014 Update. J. Oral Maxillofac. Surg. 2014, 72, 1938–1956. [Google Scholar] [CrossRef]
  3. Yarom, N.; Shapiro, C.L.; Peterson, D.E.; Van Poznak, C.H.; Bohlke, K.; Ruggiero, S.L.; O’Ryan, F. Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline. J. Clin. Oncol. 2019, 37, 2270–2290. [Google Scholar] [CrossRef]
  4. Vigarios, N.P.; Epstein, J.B.; Sibaud, V. Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors. Support Care Cancer 2017, 25, 1713–1739. [Google Scholar]
  5. Keribin, P.; Guerrot, D.; Jardin, F.; Moizan, H. Osteonecrosis of the Jaw in a Patient Presenting with Post-Transplantation Lymphoproliferative Disorder Treated With Rituximab: A Case Report. J. Oral Maxillofac. Surg. 2017, 75, 2599–2605. [Google Scholar] [CrossRef]
  6. Maluf, G.; Pinho, M.C.D.; Cunha, S.R.D.B.D.; Santos, P.S.D.S.; Fregnani, E.R. Surgery Combined with LPRF in Denosumab Osteonecrosis of the Jaw: Case Report. Braz. Dent. J. 2016, 27, 353–358. [Google Scholar] [CrossRef]
  7. Pichardo, S.E.C.; Kuypers, S.C.C.; van Merkesteyn, J.P.R. Denosumab osteonecrosis of the mandible: A new entity? A case report. J. Craniomaxillofac. Surg. 2013, 41, e65–e69. [Google Scholar] [CrossRef]
  8. Niibe, K.; Ouchi, T.; Iwasaki, R.; Nakagawa, T.; Horie, N. Osteonecrosis of the jaw in patients with dental prostheses being treated with bisphosphonates or denosumab. J. Prosthodont. Res. 2015, 59, 3–5. [Google Scholar] [CrossRef]
  9. Badr, M.; Kyriakidou, E.; Atkins, S.; Harrison, S. Aggressive denosumab-related jaw necrosis—A case series. Br. Dent. J. 2017, 223, 13–16. [Google Scholar] [CrossRef] [PubMed]
  10. Nifosi, A.F.; Nifosi, L.; Nifosi, G. Osteonecrosis of the Jaw in a patient treated with denosumab and temsirolimus. SAJ Case Rep. 2017, 4, 1–4. [Google Scholar]
  11. Allegra, A.; Oteri, G.; Alonci, A.; Bacci, F.; Penna, G.; Minardi, V.; Maisanoa, V.; Musolino, C. Association of osteonecrosis of the jaws and POEMS syndrome in a patient assuming rituximab. J. Craniomaxillofac. Surg. 2014, 42, 279–282. [Google Scholar] [CrossRef] [PubMed]
  12. Baur, D.A.; Weber, J.M.; Collette, D.C.; Dhaliwal, H.; Quereshy, F. Osteonecrosis of the Jaws Unrelated to Bisphosphonate Exposure: A Series of 4 Cases. J. Oral Maxillofac. Surg. 2012, 70, 2802–2808. [Google Scholar] [CrossRef]
  13. Javelot, M.-J.; Sergheraert, J.; Agbo-Godeau, S.; Levy-Weil, F.; Laurence, S.; Goudot, P.; Khonsarie, R.-H.; Mauprivezb, C. Rituximab as a trigger factor of medication-related osteonecrosis of the jaw. A case report. J. Stomatol. Oral Maxillofac. 2020, 121, 300–304. [Google Scholar] [CrossRef]
  14. Weigert, K.; Lewgoy, J.; Mazzoleni, D.S.; Franco, F.R.; Lisandra, E.; Henrique Sasso, J. Rituximab and osteonecrosis of the jaws: Case study. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 2014, 117, e188–e189. [Google Scholar] [CrossRef]
  15. Manzie, T.; Vujcich, N.; Chan, A. Osteonecrosis of the jaw in an anti-resorptive naïve patient taking trastuzumab and pertuzumab: Case report. Aust. Dent. J. 2020, 65, 305–307. [Google Scholar] [CrossRef]
  16. Mauceri, R.; Panzarella, V.; Morreale, I.; Campisi, G. Medication-related osteonecrosis of the jaw in a cancer patient receiving lenvatinib. Int. J. Oral Maxillofac. Surg. 2019, 48, 1530–1532. [Google Scholar] [CrossRef] [PubMed]
  17. Fleissig, Y.; Regev, E.; Lehman, H. Sunitinib related osteonecrosis of jaw: A case report. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 2012, 113, e1–e3. [Google Scholar] [CrossRef] [PubMed]
  18. Brunello, A.; Saia, G.; Bedogni, A.; Scaglione, D.; Basso, U. Worsening of osteonecrosis of the jaw during treatment with sunitinib in a patient with metastatic renal cell carcinoma. Bone 2009, 44, 173–175. [Google Scholar] [CrossRef]
  19. Koch, F.P.; Walter, C.; Hansen, T.; Jäger, E.; Wagner, W. Osteonecrosis of the jaw related to sunitinib. Oral Maxillofac. Surg. 2011, 15, 63–66. [Google Scholar] [CrossRef] [PubMed]
  20. Melloni, C.; Tuttolomondo, A.; Anfosso, A.; Calamia, C.; Clemente, F.D.; Cordova, A. Sunitinib related osteonecrosis of the jaw (SURONJ): A rare occurrence? Eur. J. Plast. Surg. 2016, 39, 161–162. [Google Scholar] [CrossRef]
  21. Nicolatou-Galitis, O.; Schiødt, M.; Mendes, R.A.; Ripamonti, C.; Hope, S.; Drudge-Coates, L.; Niepel, D.; Van den Wyngaert, T. Medication-related osteonecrosis of the jaw: Definition and best practice for prevention, diagnosis, and treatment. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 2019, 127, 117–135. [Google Scholar] [CrossRef]
  22. Agrillo, A.; Nastro Siniscalchi, E.; Facchini, A.; Filiaci, F.; Ungari, C. Osteonecrosis of the jaws in patients assuming bisphosphonates and sunitinib: Two case reports. Eur. Rev. Med. Pharmacol. Sci. 2012, 16, 952–957. [Google Scholar]
  23. Watters, A.L.; Epstein, J.B.; Agulnik, M. Oral complications of targeted cancer therapies: A narrative literature review. Oral Oncol. 2011, 47, 441–448. [Google Scholar] [CrossRef]
  24. Cillo, J.E.; Barbosa, N. Adalimumab-Related Dental Implant Infection. J. Oral Maxillofac. Surg. 2019, 77, 1165–1169. [Google Scholar] [CrossRef]
  25. Filler, S.G.; Yeaman, M.R.; Sheppard, D.C. Tumor Necrosis Factor Inhibition and Invasive Fungal Infections. Clin. Infect. Dis. 2005, 41, S208–S212. [Google Scholar] [CrossRef] [PubMed]
  26. Edwards, D.; Boritz, E.; Cowen, E.W.; Brown, R.S. Erythema multiforme major following treatment with infliximab. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 2013, 115, e36–e40. [Google Scholar] [CrossRef] [PubMed]
  27. Estilo, C.L.; Fornier, M.; Farooki, A.; Carlson, D.; Bohle, G.; Huryn, J.M. Osteonecrosis of the Jaw Related to Bevacizumab. J. Clin. Oncol. 2008, 26, 4037–4038. [Google Scholar] [CrossRef]
  28. Greuter, S.; Schmid, F.; Ruhstaller, T.; Thuerlimann, B. Bevacizumab-associated osteonecrosis of the jaw. Ann. Oncol. 2008, 19, 2091–2092. [Google Scholar] [CrossRef] [PubMed]
  29. Agostino, N.M.; Gingrich, R.; Drabick, J.J. Bevacizumab Demonstrates Prolonged Disease Stabilization in Patients with Heavily Pretreated Metastatic Renal Cell Carcinoma: A Case Series and Review of the Literature. Adv. Urol. 2010, 2010, 687043. [Google Scholar] [CrossRef]
  30. Bettini, G.; Blandamura, S.; Saia, G.; Bedogni, A. Bevacizumab-related osteonecrosis of the mandible is a self-limiting disease process. BMJ Case Rep. 2012, 2012, bcr2012007284. [Google Scholar] [PubMed]
  31. Binello, P.B.; Bandelloni, R.; Labanca, M.; Buffoli, B.; Rezzani, R.; Rodella, L.F. Osteonecrosis and the Jaws and Bevacizumab Therapy: A Case Report. Int. J. Immunopathol. Pharmacol. 2012, 25, 789–791. [Google Scholar] [CrossRef]
  32. Campisi, G.; Fedele, S.; Fusco, V.; Pizzo, G.; Di Fede, O.; Bedogni, A. Epidemiology, clinical manifestations, risk reduction and treatment strategies of jaw osteonecrosis in cancer patients exposed to antiresorptive agents. Future. Oncol. 2014, 10, 257–275. [Google Scholar] [CrossRef] [PubMed]
  33. Pakosch, D.; Papadimas, D.; Munding, J.; Kawa, D.; Kriwalsky, M.S. Osteonecrosis of the mandible due to anti-angiogenic agent, bevacizumab. Oral Maxillofac. Surg. 2013, 17, 303–306. [Google Scholar] [CrossRef] [PubMed]
  34. Santos-Silva, A.R.; Belizário Rosa, G.A.; de Castro Júnior., G.; Dias, R.B.; Prado Ribeiro, A.C.; Brandão, T.B. Osteonecrosis of the mandible associated with bevacizumab therapy. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 2013, 115, e32–36. [Google Scholar] [CrossRef] [PubMed]
  35. Serra, E.; Paolantonio, M.; Spoto, G.; Mastrangelo, F.; Tetè, S.; Dolci, M. Bevacizumab-Related Osteneocrosis of the Jaw. Int. J. Immunopathol. Pharmacol. 2009, 22, 1121–1123. [Google Scholar] [CrossRef]
  36. Tzermpos, F.; Ismail, A.; Pavli, M.; Tosios, K.I. Osteonecrosis of the mandible in a patient with lung adenocarcinoma undergoing anti-angiogenic therapy with bevacizumab: Bevacizumab associated osteonecrosis of the jaw. Oral Surg. 2016, 9, 40–46. [Google Scholar] [CrossRef]
  37. Hopp, R.N.; Pucci, J.; Santos-Silva, A.R.; Jorge, J. Osteonecrosis After Administration of Intravitreous Bevacizumab. J. Oral Maxillofac. Surg. 2012, 70, 632–635. [Google Scholar] [CrossRef] [PubMed]
  38. Erovigni, F.; Gambino, A.; Cabras, M.; Fasciolo, A.; Bianchi, S.; Bellini, E.; Fusco, V. Delayed Diagnosis of Osteonecrosis of the Jaw (ONJ) Associated with Bevacizumab Therapy in Colorectal Cancer Patients: Report of Two Cases. Dent. J. 2016, 4, 39. [Google Scholar] [CrossRef] [PubMed]
  39. Mohamed, H.A.M.; Nielsen, C.E.N.; Schiodt, M. Medication related osteonecrosis of the jaws associated with targeted therapy as monotherapy and in combination with antiresorptives. A report of 7 cases from the Copenhagen Cohort. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 2018, 125, 157–163. [Google Scholar] [CrossRef]
  40. Kim, D.W.; Jung, Y.-S.; Park, H.-S.; Jung, H.-D. Osteonecrosis of the jaw related to everolimus: A case report. Br. J. Oral Maxillofac. Surg. 2013, 51, e302–e304. [Google Scholar] [CrossRef] [PubMed]
  41. Yamamoto, D.; Tsubota, Y.; Utsunomiya, T.; Sueoka, N.; Ueda, A.; Endo, K.; Yoshikawa, K.; Kon, M. Osteonecrosis of the jaw associated with everolimus: A case report. Mol. Clin. Oncol. 2017, 6, 255–257. [Google Scholar] [CrossRef]
  42. Jung, T.-Y. Osteonecrosis of jaw after antiangiogenic agent administration in a renal cell carcinoma patient. Oral Maxillofac. Surg. Cases 2017, 3, 27–33. [Google Scholar] [CrossRef]
  43. Giancola, F.; Campisi, G.; Lo Russo, L.; Muzio, L.L.; Di Fede, O. Osteonecrosis of the jaw related to everolimus and bisphosphonate: A unique case report? Ann. Stomatol. 2013, 4, 20–21. [Google Scholar]
  44. Mawardi, H.; Enzinger, P.; McCleary, N.; Manon, R.; Villa, A.; Treister, N.; Woo, S.B. Osteonecrosis of the jaw associated with ziv-aflibercept. J. Gastrointest. Oncol. 2016, 6, e81–e87. [Google Scholar] [CrossRef]
  45. Ponzetti, A.; Pinta, F.; Spadi, R.; Mecca, C.; Fanchini, L.; Zanini, M.; Ciuffreda, L.; Racca, P. Jaw Osteonecrosisassociated with Aflibercept, Irinotecan and Fluorouracil: Attention to Oral District. Tumori 2016, 102, S74–77. [Google Scholar] [CrossRef] [PubMed]
  46. Zarringhalam, P.; Brizman, E.; Shakib, K. Medication-related osteonecrosis of the jaw associated with aflibercept. Br. J. Oral Maxillofac. Surg. 2017, 55, 314–315. [Google Scholar] [CrossRef] [PubMed]
  47. Viviano, M.; Rossi, M.; Cocca, S. A rare case of osteonecrosis of the jaw related to imatinib. J. Korean. Assoc. Oral Maxillofac. Surg. 2017, 43, 120. [Google Scholar] [CrossRef] [PubMed]
  48. Owosho, A.A.; Scordo, M.; Yom, S.K.; Randazzo, J.; Chapman, P.B.; Huryn, J.M.; Estilo, C.L. Osteonecrosis of the jaw a new complication related to Ipilimumab. Oral Oncol. 2015, 51, e100–e101. [Google Scholar] [CrossRef]
  49. Marino, R.; Orlandi, F.; Arecco, F.; Gandolfo, S.; Pentenero, M. Osteonecrosis of the jaw in a patient receiving cabozantinib. Aust. Dent. J. 2015, 60, 528–531. [Google Scholar] [CrossRef]
  50. Ebker, T.; Rech, J.; von Wilmowsky, C.; Neukam, F.W.; Stockmann, P. Fulminant course of osteonecrosis of the jaw in a rheumatoid arthritis patient following oral bisphosphonate intake and biologic therapy. Rheumatology 2013, 52, 218–220. [Google Scholar] [CrossRef]
  51. Garuti, F.; Camelli, V.; Spinardi, L.; Bucci, L.; Trevisani, F. Osteonecrosis of the Jaw during Sorafenib Therapy for Hepatocellular Carcinoma. Tumori 2016, 102, S69–S70. [Google Scholar] [CrossRef]
  52. Patel, V.; Sproat, C.; Kwok, J.; Tanna, N. Axitinib-related osteonecrosis of the jaw. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 2017, 124, e257–e260. [Google Scholar] [CrossRef] [PubMed]
  53. Antonuzzo, L.; Lunghi, A.; Giommoni, E.; Brugia, M.; Di Costanzo, F. Regorafenib Also Can Cause Osteonecrosis of the Jaw. J. Natl. Cancer. Inst. 2016, 108, djw002. [Google Scholar] [CrossRef] [PubMed]
  54. Preidl, R.H.; Ebker, T.; Raithel, M.; Wehrhan, F.; Neukam, F.W.; Stockmann, P. Osteonecrosis of the jaw in a Crohn’s disease patient following a course of Bisphosphonate and Adalimumab therapy: A case report. BMC Gastroenterol. 2014, 14, 6. [Google Scholar] [CrossRef]
  55. Cassoni, A.; Romeo, U.; Terenzi, V.; Della Monaca, M.; Rajabtork Zadeh, O.; Raponi, I.; Fadda, M.T.; Polimeni, A.; Valentini, V. Adalimumab: Another Medication Related to Osteonecrosis of the Jaws? Case. Rep. Dent. 2016, 2016, 1–6. [Google Scholar] [CrossRef]
  56. Favia, G.; Tempesta, A.; Limongelli, L.; Crincoli, V.; Iannone, F.; Lapadula, G.; Maiorano, E. A Case of Osteonecrosis of the Jaw in a Patient with Crohn’s Disease Treated with Infliximab. Am. J. Case. Rep. 2017, 18, 1351–1356. [Google Scholar] [CrossRef]
  57. Girolomoni, G.; Altomare, G.; Ayala, F.; Berardesca, E.; Calzavara-Pinton, P.; Chimenti, S.; Peserico, A.; Guerra, A.P.; Vena, G.A. Safety of anti-TNFα agents in the treatment of psoriasis and psoriatic arthritis. Immunopharmacol. Immunotoxicol. 2012, 34, 548–560. [Google Scholar] [CrossRef] [PubMed]
  58. Hasegawa, T.; Kawakita, A.; Ueda, N.; Funahara, R.; Tachibana, A.; Kobayashi, M.; Kondou, E.; Takeda, D.; Kojima, Y.; Sato, S.; et al. A multicenter retrospective study of the risk factors associated with medication-related osteonecrosis of the jaw after tooth extraction in patients receiving oral bisphosphonate therapy: Can primary wound closure and a drug holiday really prevent MRONJ? Osteoporos. Int. 2017, 28, 2465–2473. [Google Scholar] [CrossRef]
  59. Song, M. Dental care for patients taking antiresorptive drugs: A literature review. Restor. Dent. Endod. 2019, 44, e42. [Google Scholar] [CrossRef]
  60. Di Fede, O.; Panzarella, V.; Mauceri, R.; Fusco, V.; Bedogni, A.; Lo Muzio, L.; Board, S.O.; Campisi, G. The Dental Management of Patients at Risk of Medication-Related Osteonecrosis of the Jaw: New Paradigm of Primary Prevention. BioMed. Res. Int. 2018, 2018, 1–10. [Google Scholar] [CrossRef]
  61. Beth-Tasdogan, N.H.; Mayer, B.; Hussein, H.; Zolk, O. Interventions for managing medication-related osteonecrosis of the jaw. Cochrane. Database. Syst. Rev. 2017, 10, CD012432. [Google Scholar] [CrossRef]
  62. Rollason, V.; Laverrière, A.; MacDonald, L.C.I.; Walsh, T.; Tramèr, M.R.; Vogt-Ferrier, N.B. Interventions for treating bisphosphonate-related osteonecrosis of the jaw (BRONJ). Cochrane. Database. Syst. Rev. 2016, 2, CD008455. [Google Scholar] [CrossRef] [PubMed]
Figure 1. Flowchart of eligibility studies.
Figure 1. Flowchart of eligibility studies.
Applsci 11 04865 g001
Figure 2. Percentage of oral complications related to biological therapy. MRONJ is the most common oral complication registered, followed by mucosal lesion, infection, and exudative erythema multiforme.
Figure 2. Percentage of oral complications related to biological therapy. MRONJ is the most common oral complication registered, followed by mucosal lesion, infection, and exudative erythema multiforme.
Applsci 11 04865 g002
Table 1. MRONJ cases to biological therapies. Results of systematic review are shown: Author, patient’s age and sex, diseases, medication, biological therapies, causal factor of the complication, MRONJ stage, and treatment.
Table 1. MRONJ cases to biological therapies. Results of systematic review are shown: Author, patient’s age and sex, diseases, medication, biological therapies, causal factor of the complication, MRONJ stage, and treatment.
AuthorAgeSexDiseasesMedicationBiological TherapiesCausal FactorMronj StageMronj Treatment
Maluf et al. [6] (2016)69MLung cancer metastasisIrinotecan (QT)DenosumabImplant surgeryMandibular ONJ 2Surgical
44FBreast cancer and bone metastasisDexamethasone and FulvestrantDenosumab y BevacizumabEndodontic surgeryMandibular ONJ 2Surgical
Sarina et al. [7] (2013)74MProstate cancer, lung and bone metastasisQT, Bicalutamida, Goserelina, Dutasterida, Calcium y Vitamin D3 y Zoledronic acidDenosumab-Mandibular ONJ 2Surgical
Kunimichi et al. [8] (2015)60FBreast cancer-DenosumabPoorly fitting prosthesisMandibular ONJ 1-
Badr et al. [9] (2017)55FBreast cancer-DenosumabTooth extractionMandibular ONJ 3Hospitable treatment
76FBreast cancer metastasisHormone therapy and radiation therapyDenosumabTooth extractionMandibular ONJ 1Surgical
66FBone, liver and peritoneum metastasis from breast cancerQT and opioidsDenosumabTooth extractionMandibular ONJ 3Surgical
66FBone metástasis and breast cancerHormone therapy and opioids. Prior zoledronic acid therapy.DenosumabPoorly fitting prosthesisMaxillary ONJ 3Conservative
Nifosi et al. [10] (2017)47MRenal adenocarcinomaCalcium and Vitamin DTemsirolimus y Denosumab-Mandibular ONJ 2Conservative
Allegra et al. [11] (2014)56MWaldenstron’s macroglobulinemia, POEMS syndrome, lymphoplasmacytic lymphomaQT (Doxorrubicin, Cyclophosphamide, Vincristine, Prednisone)RituximabTooth extractionMandibular ONJ 2Conservative
Keribin et al. [5] (2017)69MNephropathy IgAImmunoglobulin, Ranitidine, Trimethoprim + Sulfamethoxazole,
Valganciclovir, Ofloxacin, Itraconozanol, Manidipine, Nebivolo, Perindopril, Indapamide
Rituximab y Tacrolimus-Maxillary and mandibular ONJ 2Surgical
Baur et al. [12] (2012)58MLymphoma cells BChemotherapy
(Doxorrubicin, Cyclophosphamide, Vincristine, Prednisone), Diltiazem, Atorvastatin, Meloxicam, Lisinopril, Hydroclorothiazide, Insulina, Metformin and Aspirin.
Rituximab-Mandibular ONJ 2Surgical
Javelot et al. [13] (2020)69FRheumatoid arthritisPrednisolone, Leflunomid, Valsartan y Vitamin D3. Previous treatment with Risedronate and Infliximab.RituximabHerpetic gingivostomatitisMandibular ONJ 2Surgical
Weigert et al. [14] (2014)39MNon- Hogdkin lymphomaCiclofosfamide, Vincristine, Doxorrubicin y PrednisoneRituximab-Mandibular ONJ 0Conservative
Manzie et al. [15] (2019)76FBreast cancer metastasisChemotherapy, Carboplatin, Gemcitabine, Epirubicine, Paclitaxel, Amlodipine, IrebsartanTrastuzumab + Pertuzumab-Mandibular ONJ 2Surgical
Mauceri et al. [16] (2019)58MHurtle’s cell carcinoma, lung metastasisRadiotherapy, chemotherapy (Doxorrubicin, Cisplatin), Ciclofosfamide, MetrotexateLenvatinibTooth extractionMaxillary ONJ 1Conservative
Fleissig et al. [17] (2012)58FRenal carcinoma, OsteoporosisLevothyroxine sodiumSunitinibTooth extractionMandibular ONJ 2Conservative
Brunello et al. [18] (2009)59MRenal carcinoma with ischial and pulmonary metastasisPrevious zoledronic acidSunitinib-Mandibular ONJ 2Conservative
Koch et al. [19] (2011)59MRenal carcinoma, soft tissues metastasisInterferon, Vinblastine, Ramipril, Hydroclorothiazide, Metropolol, LevothyroxineSorafenib y SunitibTooth extractionMandibular ONJ 1Surgical
Melloni et al. [20] (2016)62MRenal carcinoma, cutaneous metastasisInterferon, IL-2SunitinibTooth extractionMandibular ONJ 3Surgical
Nicolatou-Galitis et al. [21] (2012)19FRenal carcinomaCisplatinSunitinib y Everolimus-Mandibular ONJ 2Conservative
64FRenal carcinomaPrednisolone,
SunitinibProsthesis traumaMandibular ONJ 2Surgical
Agrillo et al. [22] (2012)65MRenal carcinomaPrevious zoledronic acidSunitinib-ONJ 3 maxilarSurgical
67MRenal carcinomaPrevious zoledronic acidSunitinib y Temsirolimus-Mandibular ONJ 3Surgical
Estilo et al. [27] (2008)33FGlioblastoma multiformeRadiotherapy, TemozolomideBevacizumab-Mandibular ONJ 2-
51FInfiltrating ductal carcinomaChemotherapy(Doxorrubicin+ciclofosfamide, hormonal therapy, Paclitaxel, radiotherapy, CapecitabineBevacizumab-Mandibular ONJ 2Surgical
Greuter et al. [28] (2008)63FBreast cancerDoxorrubicinBevacizumabTooth extractionMaxillary ONJ 3Surgical
Agostino et al. [29] (2010)73MRenal carcinoma-Sunitinib,
Temsirolimus y
76MRenal carcinomaIL-2Sorafenib, Sunitinib, Temsirolimus y Bevacizumab---
68MRenal carcinomaIL-2Sunitinib, Everolimus y Bevacizumab---
58FRenal carcinomaIL-2Sunitinib, Sorafenib, Temsirolimus y Bevacizumab---
Bettini et al. [30] (2012)57FLung cancerChemotherapy,
Gentamicine, Cisplatin, Corticosteroids, Lincomicine
Bevacizumab-Mandibular ONJ 2 mandibularSurgical
Brunamonti et al. [31] (2012)47MAdenocarcinomaEpirubicin+CisplatinBevacizumab-Mandibular ONJ 2Surgical
Fusco et al. [32] (2014)60MRectal cancer, lung metastasisChemotherapy and radiotherapyBevacizumabTooth extractionMandibular ONJ 2Conservative
Pakosch et al. [33] (2013)53FPancreas cancerGemcitabine, Folinic acid, Oxaliplatin, PaclitaxelErlotinib, Bevacizumab y SorafenibPoorly fitted prosthesisMandibular ONJ 2Surgical
Santos-Silva et al. [34] (2013)61MRenal carcinomaCaptopril, HidroclorotiazideBevacizumab y Temsirolimus-Mandibular ONJ 2Conservative
Serra et al. [35] (2009)64MLung adenocarcinomaCisplatin, GemcitabineBevacizumab-Mandibular ONJ 2Surgical
Tzermpos et al. [36] (2014)69MLung cancerChemotherapy (Carboplatin+ Docetaxel), CortisoneBevacizumabPoorly fitted prosthesisMandibular ONJ 2Surgical
Hopp et al. [37] (2012)58MRetinal vascular thrombosis-Bevacizumab-Mandibular ONJ 2Surgical
Erovigni et al. [38] (2016)79MColon adenocarcinomaCapecitabin, Oxaliplatin, Fluoracil, Folínic acid, Irinotecan, radiotherapyBevacizumabTooth extractionMandibular ONJ 2Conservative
60MRectal cancer, lung and brain metastasisChemotherapy and radiotherapyBevacizumabTooth extractionMandibular ONJ 2Conservative
Mawardi et al. [44] (2016)43MMetastasis of colorectal carinoma5-fluorouracil, Leucovorin, IrinotecanAflibercept-Mandibular ONJ 1Surgical
63MGastrointestinal metastatuc carcinoid5-fluorouracil, Leucovorin and OxaliplatinAflibercept-Mandibular ONJ 1Conservative
51MEsophageal carcinoma metastasis-AfliberceptTooth extractionMandibular ONJ 1Conservative
Ponzetti et al. [45] (2016)64FMetastasis of colorectal carinoma5-fluoracil, Irinotecan and Levofolinic AcidAflibercept-Mandibular ONJ 1Conservative
Zarringhalam et al. [46] (2017)47MIntestine, liver, peritoneum and pelvis metastasis-Aflibercept-Mandibular ONJ 1Conservative
Viviano et al. [47] (2017)72MGastrointestinal stromal tumor-ImatinibTooth extractionMandibular ONJ 2Surgical
Owosho et al. [48] (2015)52MMelanoma metastasis in the iliac region and pancreas-Ipilimumab-Mandibular ONJ 2Surgical
Kim et al. [40] (2013)52MBone metastasis from thyroid cancerPrevious zoledronc acid treatmentEverolimus-Mandibular ONJ 2Conservative
Yamamoto et al. [41] (2017)80FBreast cancerCapecitabine, Tamoxifen, Fulvestrant y ExemestanEverolimus-Mandibular ONJ 2Conservative
Jung et al. [42] (2017)62FRenal carcinoma-Everolimus y PazopanibImplant surgeryMandibular ONJ 2Surgical
Giancola et al. [43] (2013)64MRenal carcinoma metastasisPrevious zoledronc acid treatmentEverolimus-Mandibular ONJ 2Surgical
Garuti et al. [51] (2017)74MHepatic cancer-SorafenibTooth extractionMandibular ONJ 1Conservative
Marino et al. [49] (2015)51FLiver and lymph nodes metástasis from thyroid cancerLevotiroxine, Calcitriol, Vitamin D3, Duloxetine, Propanolol, Lansoprazole y LoperamideCabozantinibTooth extractionMandibular ONJ 2Surgical
Mohamed et al. [39] (2018)70MRenal carcinoma-Sunitinib, Everolimus, PazopanibTooth extractionMandibular ONJ 1Conservative
53FLung cancerCarboplatin, Cisplatin, Vironelbine ZoledronicErlotinib, Afatinib y DenosumabTooth extractionMaxillary ONJ 2Surgical
55FLung cancerCarboplatine, Vironelbine, Alimeta.BevacizumabTooth extractionMaxillary ONJ 1Conservative
66MMultiforme glioblastomaTemozolomide, IrinotecanBevacizumabTrauma by intraoral radiographyMandibular ONJ 2Conservative
74FMultiple myelomaCyclophosphamide, Thalidomide, Alkaran, Capecitabine, Oxaliplatin, Folfiri, Irinotecan, and PamidronateBevacizumab y CetuximabSpontaneousMandibular ONJ 1Surgical
53FLeukemiaCitarabine and VincristineNilotinib y DasanitibGingival ulcerMandibular ONJ 2Surgical
81FLeukemiaCapecitabine, AlendronateTrastuzumab, Imatinib y DenosumabTooth extractionMandibular ONJ 2Surgical
Patel et al. [52] (2017)67MLung, brain, skin, hearth and pelvis metástasis from renal carcinomaAmlodipine, Ramipril, Levetiracetam, Dexamethasone, Lansoprazole, Morphine, Metoclopramide, Amiodarone hydrochloride, and Cholecalciferol. Previous treatment Pazopanib and NivolumabAxitinib-Maxillary ONJ 1Conservative
Antonuzzo et al. [53] (2016)59FMetastatic colorectal cancer-Regorafenib-Maxillary ONJ 3-
Preidl et al. [54] (2014)36FCrohn diseaseSteroids, Risedronate, Zoledronic acid, PrednisoloneAdalimumabTooth extractionMandibular ONJ 3Surgical
Cassoni et al. [55] (2016)63FIdiopathic arthritisSalazopyrinAdalimumabImplant surgeryMandibular ONJ mandibularSurgical
Favia et al. [56] (2017)49FChron disease-InfliximabTooth extractionMandibular ONJ 3 mandibularSurgical
Ekber et al. [50] (2013)74FRheumatoid arthritis and osteoporosisMethotrexate, Prednisolone, Folic Acid, Ibuprofen, Pantoprazole, Calcium, Vit. D. Previous treatment with zoledronic acid.InfliximabTooth extractionMandibular ONJ 3Surgical
TocilizumabTarthrectomyMandibular ONJ 3Surgical
Table 2. Biological therapies associated with oral complications and trade name. Most common biological therapies and trade name related to oral complications are shown.
Table 2. Biological therapies associated with oral complications and trade name. Most common biological therapies and trade name related to oral complications are shown.
DrugTrade NameCategory
AfliberceptZaltrap, EyleaFusion prothein
CabozantinibCometriq, CabometyxTKI
DenosumabXgeva, ProliaMAB
EverolimusAfinitormTOR inhibitor
RituximabErbitux, RituxanMAB
TacrolimusAdvagrafmTOR inhibitor
TemsirolimusToriselmTOR inhibitor
Trastuzumab+PertuzumabHerceptin + Perjeta MAB
TKI: tyrosine-kinase inhibitor, MAB: monoclonal antibody, mTOR: mammalian target of rapamycin.
Table 3. Complication grades divided by the AAOMS and specific treatment. Complication grades according to AAOMS and recommended treatment are shown.
Table 3. Complication grades divided by the AAOMS and specific treatment. Complication grades according to AAOMS and recommended treatment are shown.
Risk: No apparent necrotic bone Treatment not indicated, patient education
Grade 0: No clinical evidence of bone necrosis, but nonspecific clinical findings, radiographic changes, and symptoms.Systemic management, including the use of analgesics and antibiotic.
Grade 1: Exposure and bone necrosis, or fistulas that can be probed to bone in asymptomatic patients without evidence of infection.Antibacterial rinses, clinical follow-up, patient education.
Grade 2: Exposure and bone necrosis, or fistulas that can be probed to the bone, associated with infection with pain or erythema in the region of exposed bone with or without purulent drainage. Symptomatic treatment with oral antibiotics, antibacterial rinses, pain control, debridement to relieve soft tissue irritation and control infection.
Grade 3: Presence of one of the following signs: bone exposure and necrosis that extends beyond the alveolar region, pathological fractures, extraoral fistulas, oro-nasal or oro-antral communication, osteolysis that extends to the lower border of the mandible or floor of the breast.Antibacterial rinses, antibiotic therapy and pain control, surgical debridement or resection to alleviate infection and long-lasting pain.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Back to TopTop